Gracell Biotechnologies Inc. (GRCL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gracell Biotechnologies Inc. (GRCL) has a cash flow conversion efficiency ratio of -0.029x as of March 2021. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-63.95 Million) by net assets ($2.19 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Gracell Biotechnologies Inc. - Cash Flow Conversion Efficiency Trend (2018–2022)
This chart illustrates how Gracell Biotechnologies Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read GRCL total debt and obligations for a breakdown of total debt and financial obligations.
Gracell Biotechnologies Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gracell Biotechnologies Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hnac Technology Co Ltd
SHE:300490
|
0.023x |
|
Shentong Technology Group Co Ltd
SHG:605228
|
0.058x |
|
SY HOLDINGS GROUP HD-01
F:9U0
|
N/A |
|
Decai Decoration Co Ltd
SHG:605287
|
0.009x |
|
Preformed Line Products Company
NASDAQ:PLPC
|
0.041x |
|
G R Infraprojects Limited
NSE:GRINFRA
|
0.045x |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
0.055x |
|
Zhejiang Vie Science & Technology Co Ltd
SHE:002590
|
0.045x |
Annual Cash Flow Conversion Efficiency for Gracell Biotechnologies Inc. (2018–2022)
The table below shows the annual cash flow conversion efficiency of Gracell Biotechnologies Inc. from 2018 to 2022. For the full company profile with market capitalisation and key ratios, see how much is Gracell Biotechnologies Inc. worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $1.38 Billion | $-3.31 Billion | -2.404x | -1342.35% |
| 2021-12-31 | $1.83 Billion | $-304.55 Million | -0.167x | +31.06% |
| 2020-12-31 | $819.66 Million | $-198.15 Million | -0.242x | +54.41% |
| 2019-12-31 | $255.36 Million | $-135.39 Million | -0.530x | +97.96% |
| 2018-12-31 | $2.38 Million | $-61.86 Million | -25.957x | -- |
About Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enable… Read more